Table 3.
Adverse events and other COVID-19 related drugs
| Total (n = 124) | Lopinavir/Ritonavir (n = 62) | Atazanavir/Ritonavir (n = 62) | P -value | |
|---|---|---|---|---|
| Adverse events, n (%) | ||||
| Hemoptysis | 4 (3.2) | 3 (4.8) | 1 (1.6) | 0.61 |
| Icterus | 2 (1.6) | 0 (0) | 2 (3.2) | 0.49 |
| Dysentery | 2 (1.6) | 1 (1.6) | 1 (1.6) | ≥0.99 |
| Dizziness | 2 (1.6) | 2 (3.2) | 0 (0) | 0.49 |
| Fever | 2 (1.6) | 1 (1.6) | 1 (1.6) | ≥0.99 |
| Nausea and vomiting | 8 (6.5) | 8 (12.9) | 0 (0) | 0.006 |
| Hiccups | 2 (1.6) | 0 (0) | 2 (3.2) | 0.49 |
| Chest pain | 1 (0.8) | 1 (1.6) | 0 (0) | ≥0.99 |
| Other COVID-19 related drugs, n (%) | ||||
| Ribavirin | 1 (0.8) | 1 (1.6) | 0 (0) | ≥0.99 |
| Remdesivir | 17 (13.7) | 10 (16.1) | 7 (11.3) | 0.60 |
| Corticosteroid | 53 (42.7) | 27 (43.5) | 26 (41.9) | ≥0.99 |
| Intravenous Immunoglobulin (IVIG) | 6 (4) | 3 (4.8) | 2 (3.2) | ≥0.99 |
| Interferon | 91 (74) | 48 (77.4) | 43 (70.5) | 0.41 |
| NSAIDs | 110 (88.7) | 58 (93.5) | 52 (83.9) | 0.15 |
| Azithromycin | 63 (50.8) | 34 (54.8) | 29 (46.8) | 0.47 |
| Ceftriaxone | 80 (64.5) | 36 (58.1) | 44 (71) | 0.18 |
| Enoxaparin/Heparin | 112 (90.3) | 54 (87.1) | 58 (93.5) | 0.36 |
| Favipiravin | 5 (4) | 4 (6.5) | 1 (1.6) | 0.36 |
| Tocilizumab | 4 (3.2) | 2 (3.2) | 2 (3.2) | ≥0.99 |
| Sofosbuvir/Daclatasvir | 23 (18.7) | 15 (24.2) | 8 (13.1) | 0.16 |
NSAID: non-steroidal anti-inflammatory drug.